Optimi Health Completes Psilocybin Export to Australia for Patients With Treatment-Resistant Depression
Optimi Health completed its third commercial export of 5mg psilocybin capsules to Australia for the treatment of treatment-resistant depression. The shipment of 1,000 capsules was produced at the company's GMP facility in British Columbia and is eligible for reimbursement by public and private payers including the Department of Veterans' Affairs.
Key figures
- Dosage mg
- 5
- Clinicians trained
- 750
- Shipment quantity capsules
- 1000
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.